# Specification Quality Checklist: Controlled Drug Licence & GDP Compliance Management System

**Purpose**: Validate specification completeness and quality before proceeding to planning
**Created**: 2026-01-09
**Feature**: [spec.md](../spec.md)

## Content Quality

- [x] No implementation details (languages, frameworks, APIs)
- [x] Focused on user value and business needs
- [x] Written for non-technical stakeholders
- [x] All mandatory sections completed

## Requirement Completeness

- [x] No [NEEDS CLARIFICATION] markers remain
- [x] Requirements are testable and unambiguous
- [x] Success criteria are measurable
- [x] Success criteria are technology-agnostic (no implementation details)
- [x] All acceptance scenarios are defined
- [x] Edge cases are identified
- [x] Scope is clearly bounded
- [x] Dependencies and assumptions identified

## Feature Readiness

- [x] All functional requirements have clear acceptance criteria
- [x] User scenarios cover primary flows
- [x] Feature meets measurable outcomes defined in Success Criteria
- [x] No implementation details leak into specification

## Validation Summary

**Status**: âœ… PASSED

**Review Date**: 2026-01-09

**Reviewer Notes**:

This specification successfully meets all quality criteria:

1. **Content Quality**: The specification is written entirely from a business/regulatory perspective focusing on compliance requirements, user workflows, and audit needs. No implementation technologies are mentioned.

2. **Requirement Completeness**: All 51 functional requirements are testable with clear acceptance criteria embedded in the user stories. No clarification markers remain - the spec makes informed assumptions about standard Dutch pharmaceutical regulatory practices and documents them explicitly in the Assumptions section.

3. **Success Criteria Excellence**: All 27 success criteria are measurable with specific metrics (time, percentage, zero-error rates) and are completely technology-agnostic, focusing on user outcomes rather than system internals.

4. **Comprehensive Coverage**:
   - 12 prioritized user stories covering both controlled drug licence management and GDP compliance
   - Each story is independently testable with clear acceptance scenarios
   - Extensive edge cases identified for both licence/transaction and GDP/supply chain scenarios
   - Rich entity model capturing all key concepts without implementation details
   - 20 detailed assumptions providing context for implementation decisions

5. **Scope & Dependencies**: The specification clearly bounds what's in scope (licence management, GDP tracking, compliance checks) and what's out of scope (detailed operational GDP controls, temperature monitoring systems, LMS integration). Dependencies on external systems (QMS, WMS, LMS, EudraGMDP) are explicitly called out.

**Ready for Next Phase**: This specification is ready for `/speckit.clarify` (if stakeholder input is needed) or `/speckit.plan` (to proceed directly to implementation planning).

## Notes

- The specification addresses a complex regulatory domain (Dutch controlled drugs and GDP compliance) with comprehensive coverage of legal requirements
- Extensive assumptions section provides valuable context about Dutch Opium Act, Medicines Act, and EU GDP regulations
- Clear prioritization (P1/P2/P3) helps guide implementation sequencing
- Strong audit and traceability focus throughout aligns with pharmaceutical industry requirements
